SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Revelation Biosciences, Inc. (REVB) News

Follow Revelation Biosciences, Inc. (REVB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol REVB Asset equity Sector Markets 90 days 3 Last 3.77 Updated Nov 05, 2026, 10:38 PM UTC Open live news feed Open REVB chart & news
M Revelation Biosciences Q3 Net Loss Widens on Gemini Development Costs EQUITY | Nov 05, 2026, 10:38 PM UTC L Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary Revelation Biosciences reported a wider quarterly net loss than a year earlier as research and development and general and administrative expenses increased. The company said higher GEM-AKI program and manufacturing cost EARNINGS | Nov 05, 2026, 10:33 PM UTC M Revolution Beauty Group expects H1 FY27 adjusted EBITDA Revolution Beauty Group PLC said it expects to report first-half FY27 adjusted EBITDA of not less than £2 mln. EARNINGS | Sep 17, 2026, 06:42 AM UTC L Revelation Biosciences selects Avance Clinical as CRO for Titan Phase 2/3 Revelation Biosciences (REVB) selects Avance Clinical as CRO for its Phase 2/3 Titan study, which is expected to begin later this year. EQUITY | Aug 19, 2026, 01:05 PM UTC L Revelation Biosciences hires Avance Clinical as CRO for TITAN Phase 2/3 Revelation Biosciences (REVB) selects Avance Clinical as the CRO for its Phase 2/3 TITAN study. EQUITY | Aug 19, 2026, 01:04 PM UTC L REVB - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury REVB - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury EQUITY | Aug 03, 2026, 01:00 PM UTC